Earnings Before Tax (EBT)
The latest quarterly ebt is $113.00 Million with a quarter-over-quarter change of -19.40%. Earnings Before Tax (EBT), also called pre-tax income, represents a company's profit after all operating and non-operating expenses but before income tax expense.
PODD EBT
Reported quarterly EBT; no daily interpolation.
Current EBT
$113.00M
$113.00 Million
Quarter-over-Quarter Change
-19.40%
vs. $140.20M prior quarter
Historical Data
85
Quarters of data available
Quarterly EBT History
| Period | EBT | QoQ Change | % Change |
|---|---|---|---|
| Q1 2026 | $113.00M | $-27.20M | -19.40% |
| Q4 2025 | $140.20M | +$17.40M | +14.17% |
| Q3 2025 | $122.80M | +$94.40M | +332.39% |
| Q2 2025 | $28.40M | $-19.70M | -40.96% |
| Q1 2025 | $48.10M | $-63.20M | -56.78% |
| Q4 2024 | $111.30M | +$28.40M | +34.26% |
| Q3 2024 | $82.90M | +$31.80M | +62.23% |
| Q2 2024 | $51.10M | $-3.80M | -6.92% |
| Q1 2024 | $54.90M | $-52.90M | -49.07% |
| Q4 2023 | $107.80M | +$54.10M | +100.74% |
| Q3 2023 | $53.70M | +$25.20M | +88.42% |
| Q2 2023 | $28.50M | +$3.90M | +15.85% |
| Q1 2023 | $24.60M | +$2.30M | +10.31% |
| Q4 2022 | $22.30M | +$28.00M | +491.23% |
| Q3 2022 | $-5.70M | +$30.40M | +84.21% |
| Q2 2022 | $-36.10M | $-65.40M | -223.21% |
| Q1 2022 | $29.30M | $-4.10M | -12.28% |
| Q4 2021 | $33.40M | +$18.20M | +119.74% |
| Q3 2021 | $15.20M | +$43.60M | +153.52% |
| Q2 2021 | $-28.40M | $-28.70M | -9566.67% |
| Q1 2021 | $300,000 | +$18.80M | +101.62% |
| Q4 2020 | $-18.50M | $-31.90M | -238.06% |
| Q3 2020 | $13.40M | $-4.00M | -22.99% |
| Q2 2020 | $17.40M | +$20.00M | +769.23% |
| Q1 2020 | $-2.60M | $-9.38M | -138.34% |
| Q4 2019 | $6.78M | +$5.68M | +516.55% |
| Q3 2019 | $1.10M | $-800,000 | -42.11% |
| Q2 2019 | $1.90M | $-2.80M | -59.57% |
| Q1 2019 | $4.70M | $-6.19M | -56.83% |
| Q4 2018 | $10.89M | +$9.04M | +487.59% |
| Q3 2018 | $1.85M | +$3.13M | +244.88% |
| Q2 2018 | $-1.28M | +$4.96M | +79.49% |
| Q1 2018 | $-6.24M | +$685,000 | +9.90% |
| Q4 2017 | $-6.92M | $-4.82M | -228.63% |
| Q3 2017 | $-2.11M | +$5.56M | +72.53% |
| Q2 2017 | $-7.67M | +$2.21M | +22.42% |
| Q1 2017 | $-9.88M | $-925,000 | -10.33% |
| Q4 2016 | $-8.96M | $-6.00M | -203.49% |
| Q3 2016 | $-2.95M | +$1.33M | +31.15% |
| Q2 2016 | $-4.29M | +$6.34M | +59.66% |
| Q1 2016 | $-10.63M | +$16.56M | +60.92% |
| Q4 2015 | $-27.19M | $-9.25M | -51.54% |
| Q3 2015 | $-17.94M | $-689,000 | -3.99% |
| Q2 2015 | $-17.25M | $-6.83M | -65.60% |
| Q1 2015 | $-10.42M | $-5.02M | -93.07% |
| Q4 2014 | $-5.40M | +$5.43M | +50.15% |
| Q3 2014 | $-10.82M | +$18.23M | +62.75% |
| Q2 2014 | $-29.06M | $-22.98M | -378.02% |
| Q1 2014 | $-6.08M | $-3.42M | -129.05% |
| Q4 2013 | $-2.65M | +$18.63M | +87.53% |
| Q3 2013 | $-21.29M | $-10.88M | -104.64% |
| Q2 2013 | $-10.40M | +$133,000 | +1.26% |
| Q1 2013 | $-10.53M | $-409,000 | -4.04% |
| Q4 2012 | $-10.13M | +$2.26M | +18.27% |
| Q3 2012 | $-12.39M | +$2.02M | +14.01% |
| Q2 2012 | $-14.41M | +$327,000 | +2.22% |
| Q1 2012 | $-14.73M | $-14.73M | — |
| Q4 2011 | $0 | +$13.56M | +100.00% |
| Q3 2011 | $-13.56M | +$5.86M | +30.18% |
| Q2 2011 | $-19.42M | $-9.57M | -97.23% |
| Q1 2011 | $-9.85M | $-9.85M | — |
| Q4 2010 | $0 | +$0 | — |
| Q3 2010 | $0 | +$0 | — |
| Q2 2010 | $0 | +$0 | — |
| Q1 2010 | $0 | +$0 | — |
| Q4 2009 | $0 | +$0 | — |
| Q3 2009 | $0 | +$0 | — |
| Q2 2009 | $0 | +$0 | — |
| Q1 2009 | $0 | +$0 | — |
| Q4 2008 | $0 | +$0 | — |
| Q3 2008 | $0 | +$0 | — |
| Q2 2008 | $0 | +$0 | — |
| Q1 2008 | $0 | +$0 | — |
| Q4 2007 | $0 | +$0 | — |
| Q3 2007 | $0 | +$0 | — |
| Q2 2007 | $0 | +$0 | — |
| Q1 2007 | $0 | +$0 | — |
| Q4 2006 | $0 | +$0 | — |
| Q3 2006 | $0 | +$0 | — |
| Q2 2006 | $0 | +$0 | — |
| Q1 2006 | $0 | +$0 | — |
| Q4 2005 | $0 | +$0 | — |
| Q3 2005 | $0 | +$0 | — |
| Q2 2005 | $0 | +$0 | — |
| Q1 2005 | $0 | — | — |
About Insulet Corp.
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Ashley A. McEvoy